Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared a post on LinkedIn:
“Adjuvant RT Alone vs. CRT in Cervical Cancer: Do We Really Need Chemo?
What we know?
Adjuvant RT reduces recurrence in intermediate-risk cervical cancer.
The gap:
Unclear if adding cisplatin improves outcomes after surgery.
The trial:
NRG/GOG-263, Phase III, 316 patients (stage IB–IIA) randomized To adjuvant RT vs CRT after surgery.
Results:
• 3-year RFS: 88.5% (CRT) vs 85.4% (RT), not significant.
• OS trend favored CRT, but not significant.
• Toxicity: Grade 3–4 events 43% with CRT vs 15% with RT.
Clinical impact:
RT alone remains highly effective, especially with IMRT. Adding cisplatin increases toxicity without clear survival gain.
See more.”
